BioSpace News Archive

Synthego, the genome engineering company, announced that the company has broken ground on a 20,000-square-foot manufacturing facility designed to accelerate translational and clinical research development timelines for cell and gene therapies to as little as a year.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced a tender offer (the “Offer”) to purchase any and all of its outstanding 3.25% Convertible Senior Notes due 2023 (the “Convertible Notes”).

Affini-T Therapeutics, Inc ., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Dirk Nagorsen, M.D., as the company’s Chief Medical Officer.

Exo (pronounced “echo”), a pioneering health information and medical devices company, today announced that it is acquiring Medo, a Canadian developer of artificial intelligence (AI) technology, to make ultrasound imaging faster and simpler to use.

Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus, for research use only.

In order to bring new cutting-edge research models to the market to accelerate the development of novel therapeutics for a host of unmet medical needs, particularly in immuno-oncology, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has entered into a strategic license agreement with Charles River Laboratories, Inc. for exclusive distribution of its next generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America.

City of Hope, one of the largest cancer research and treatment organizations in the United States, was recognized as the seventh “Best Hospital” for cancer in the nation according to U.S. News & World Report’s 2022-23 Best Hospitals: Specialty Ranking.

LumiThera Inc., a commercial stage medical device company offering photobiomodulation treatment for ocular damage and disease, announced the purchase of MacuLogix assets by its wholly owned subsidiary.

Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the full commercial launch of the FORTOS-C™ Anterior Cervical Plating System.

Athersys, Inc. will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.